{"entity":{"id":"acasunlimab","kind":"drug","name":"Acasunlimab","aka":["DuoBody®-PD-L1×4-1BB"],"tldr":"Acasunlimab is an experimental bispecific antibody from Genmab in phase 3 trials for non-small-cell lung cancer, aimed at PD-L1.","summary":"Acasunlimab (GEN1046) is a bispecific antibody developed by Genmab. Its target is PD-L1 (the sponsor names PD-L1 x 4-1BB (CD137)). The sponsor states: Acasunlimab (GEN1046, DuoBody-PD-L1x4-1BB) is a bispecific antibody that co-targets PD-L1 and the costimulatory receptor 4-1BB, given intravenously in combination with pembrolizumab versus docetaxel in PD-L1-positive metastatic NSCLC that progressed after prior anti-PD-(L)1 therapy and chemotherapy. ClinicalTrials.gov describes the intervention as: Acasunlimab will be administered intravenously (IV). It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06635824 (Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)), in non-small-cell lung cancer. The largest, NCT06635824, plans to enrol 191 participants (actual) with primary completion expected 2027-07-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Acasunlimab","url":"https://clinicaltrials.gov/search?intr=GEN1046"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["pdl1","cd137"],"drugs":[],"companies":["genmab"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06635824","nct05117242"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"GEN1046","modality":"bispecific antibody","mechanism":"Acasunlimab (GEN1046, DuoBody-PD-L1x4-1BB) is a bispecific antibody that co-targets PD-L1 and the costimulatory receptor 4-1BB, given intravenously in combination with pembrolizumab versus docetaxel in PD-L1-positive metastatic NSCLC that progressed after prior anti-PD-(L)1 therapy and chemotherapy.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/acasunlimab/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"cd137","kind":"target","name":"CD137 (4-1BB, TNFRSF9)","route":"/targets/cd137/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"company":[{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/"}],"trial":[{"id":"nct05117242","kind":"trial","name":"Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer","route":"/trials/nct05117242/"},{"id":"nct06635824","kind":"trial","name":"Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)","route":"/trials/nct06635824/"}]}}